Fiche publication


Date publication

septembre 2017

Journal

Journal for immunotherapy of cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Dr LIMACHER Jean-Marc


Tous les auteurs :
Tosch C, Bastien B, Barraud L, Grellier B, Nourtier V, Gantzer M, Limacher JM, Quemeneur E, Bendjama K, Préville X

Résumé

Advanced non-small cell lung cancer patients receiving TG4010, a therapeutic viral vaccine encoding human Mucin 1 and interleukin-2 in addition to standard chemotherapy, displayed longer overall survival in comparison to that of patients treated with standard chemotherapy alone. Our study intended to establish the association between overall survival and vaccine-induced T cell responses against tumor associated antigens (TAA) targeted by the vaccine.

Mots clés

Cancer vaccine, Lung cancer, T cell response, Tumor associated antigen, Viral vaccine

Référence

J Immunother Cancer. 2017 Sep;5(1):70